Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
MedPage Today on MSN5d
T-Cell Rebalancing Therapy Active in Previously Treated Atopic DermatitisA novel therapy for atopic dermatitis (AD) led to at least 75% improvement in a third of patients after 6 months, a ...
Clinical Trials Arena on MSN5d
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpointsAll the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.
The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving statistical significance for both rocatinlimab dose ...
THOUSAND OAKS, Calif. and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...
Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback